Assessment of the advantage of the serum S100B protein biomonitoring in the management of paediatric mild traumatic brain injury-PROS100B: protocol of a multicentre unblinded stepped wedge cluster randomised trial.
biochemistry
paediatrics
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 05 2019
24 05 2019
Historique:
entrez:
27
5
2019
pubmed:
28
5
2019
medline:
12
6
2020
Statut:
epublish
Résumé
S100B serum analysis in clinical routine could reduce the number of cranial CT (CCT) scans performed on children with mild traumatic brain injury (mTBI). Sampling should take place within 3 hours of trauma and cut-off levels should be based on paediatric reference ranges. The aim of this study is to evaluate the utility of measuring serum S100B in the management of paediatric mTBI by demonstrating a decrease in the number of CCT scans prescribed in an S100B biomonitoring group compared with a 'conventional management' control group, with the assumption of a 30% relative decrease of the number of CCT scans between the two groups. The protocol is a randomised, multicentre, unblinded, prospective, interventional study (nine centres) using a stepped wedge cluster design, comparing two groups (S100B biomonitoring and control). Children in the control group will have CCT scans or be hospitalised according to the current recommendations of the French Society of Paediatrics (SFP). In the S100B biomonitoring group, blood sampling to determine serum S100B protein levels will take place within 3 hours after mTBI and subsequent management will depend on the assay. If S100B is in the normal range according to age, the children will be discharged from the emergency department after 6 hours' observation. If the result is abnormal, CCT scans or hospitalisation will be prescribed in accordance with current SFP recommendations. The primary outcome measure will be the proportion of CCT scans performed (absence/presence of CCT scan for each patient) in the 48 hours following mTBI. The protocol presented (Version 5, 03 November 2017) has been approved by the ethics committee Comité de Protection des Personnes sud-est 6 (first approval 08 June 2016, IRB: 00008526). Participation in the study is voluntary and anonymous. The study findings will be disseminated in international peer-reviewed journals and presented at relevant conferences. NCT02819778.
Identifiants
pubmed: 31129587
pii: bmjopen-2018-027365
doi: 10.1136/bmjopen-2018-027365
pmc: PMC6537998
doi:
Substances chimiques
Biomarkers
0
S100 Calcium Binding Protein beta Subunit
0
S100B protein, human
0
Banques de données
ClinicalTrials.gov
['NCT02819778']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e027365Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Acad Emerg Med. 2016 Aug;23(8):878-84
pubmed: 27197686
Arch Pediatr. 2014 Jul;21(7):790-6
pubmed: 24935453
J Neurotrauma. 2006 Feb;23(2):149-55
pubmed: 16503799
J Cardiothorac Vasc Anesth. 2000 Dec;14(6):698-701
pubmed: 11139112
J Clin Epidemiol. 2011 Sep;64(9):936-48
pubmed: 21411284
Lancet. 2017 Jun 17;389(10087):2393-2402
pubmed: 28410792
J Intern Med. 2004 May;255(5):521-8
pubmed: 15078495
Ann Biol Clin (Paris). 2009 Jul-Aug;67(4):425-31
pubmed: 19654082
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
BMC Emerg Med. 2012 Oct 27;12:13
pubmed: 23102492
Scand J Trauma Resusc Emerg Med. 2016 Aug 04;24:98
pubmed: 27488722
Arch Phys Med Rehabil. 2014 Mar;95(3 Suppl):S265-77
pubmed: 24581912
J Neurotrauma. 2013 Mar 1;30(5):324-38
pubmed: 23078348
Int J Biochem Cell Biol. 2001 Jul;33(7):637-68
pubmed: 11390274
Pediatrics. 1999 Dec;104(6):e78
pubmed: 10586012
J Child Neurol. 2016 Jan;31(1):20-7
pubmed: 25123531
BMJ. 2006 Sep 2;333(7566):469
pubmed: 16895945
Pediatrics. 2018 Jun;141(6):
pubmed: 29716980
Lancet. 2009 Oct 3;374(9696):1160-70
pubmed: 19758692
Brain Res Bull. 1995;37(4):417-29
pubmed: 7620916
Clin Chem. 2012 Jul;58(7):1116-22
pubmed: 22529109
Med Res Rev. 2014 May;34(3):503-31
pubmed: 23813922
Int J Epidemiol. 2006 Oct;35(5):1292-300
pubmed: 16943232
Neurosurg Focus. 2010 Nov;29(5):E2
pubmed: 21039136
BMC Neurol. 2016 Oct 20;16(1):200
pubmed: 27765016
Ann Emerg Med. 2015 Jan;65(1):72-80.e6
pubmed: 25443992
J Clin Epidemiol. 2004 Aug;57(8):785-94
pubmed: 15485730
Brain Res Bull. 2003 Aug 15;61(3):281-5
pubmed: 12909298
JAMA Pediatr. 2013 Aug 1;167(8):700-7
pubmed: 23754213
BMC Med. 2015 Dec 09;13:292
pubmed: 26645914
Brain Inj. 2000 Dec;14(12):1047-55
pubmed: 11147577
Ann Emerg Med. 2001 Jan;37(1):65-74
pubmed: 11145776
BMC Med. 2016 Feb 18;14:33
pubmed: 26888597
J Rehabil Med. 2004 Feb;(43 Suppl):28-60
pubmed: 15083870
Arch Dis Child. 2016 Jun;101(6):527-532
pubmed: 26998632
Shock. 2006 May;25(5):446-53
pubmed: 16680008
J Head Trauma Rehabil. 2010 Jul-Aug;25(4):228-40
pubmed: 20611042
BMJ. 2013 May 21;346:f2360
pubmed: 23694687
Emerg Med J. 2004 Jan;21(1):54-8
pubmed: 14734377
J Trauma. 2007 Jun;62(6):1452-6
pubmed: 17563665
Acta Biomed. 2012 Apr;83(1):5-20
pubmed: 22978053
Brain Inj. 2015 Sep;29(10):1146-1157
pubmed: 26067622